The Science of Sun Protection: A JDD Dermatology Podcast Recap
A patient in my clinic was recently prescribed 5-fluorouracil for severe photodamage, diffuse actinic keratoses. He is 24 years old and, unfortunately, lacked knowledge about photoprotection. It was sobering to think about how much longer he has to live and the damage already done. Strides have been made over the years in educating our patients about photoprotection, but recently, patients have …
A patient in my clinic was recently prescribed 5-fluorouracil for severe photodamage, diffuse actinic keratoses. He is 24 years old and, unfortunately, lacked knowledge about photoprotection. It was sobering to think about how much longer he has to live and the damage already done. Strides have been made over the years in educating our patients about photoprotection, but recently, patients have … Continue reading "The Science of Sun Protection: A JDD Dermatology Podcast Recap"
Introduction
The term “skin of color” generally refers to individuals from a broad group of racial and ethnic backgrounds including, but not limited to, Black, Asian, Latinx, American Indian, and Pacific Islander, as well as those of mixed race.1 According to the U.S. Census, the population will increase to comprise over 50% persons of color by the year 2042.2 However, the demographics … 
With a special focus on patients with skin of color, the July issue of the Journal of Drugs in Dermatology is packed with outstanding articles, features, and case reports on topics ranging from OTC therapies for hair grow and choosing the right sunscreen in communities of color, to evaluation of a skin of color curriculum for dermatology residents and PLLA for correction of nasolabial folds. Stra … 
JDD authors Samuel S. Kassirer BA, Robert H. Gotkin MD, and Deborah S. Sarnoff MD present the first reported case of rhinophyma in a 62-year-old Fitzpatrick V female patient who was successfully treated with one session of fractional CO2 laser resurfacing. This case highlights the successful use of the fractional CO2 laser to treat rhinophyma in darker skin types (Fitzpatrick IV–VI) and undersco … 
INTRODUCTION
Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr … 